Revista Brasileira de Ginecologia e Obstetrícia (Dec 2012)

Síndrome metabólica em mulheres na pós-menopausa tratadas de câncer de mama Metabolic syndrome in postmenopausal breast cancer survivors

  • Eliana Aguiar Petri Nahas,
  • Bruno da Rosa de Almeida,
  • Daniel de Araújo Brito Buttros,
  • Heloísa De Luca Véspoli,
  • Gilberto Uemura,
  • Jorge Nahas-Neto

Journal volume & issue
Vol. 34, no. 12
pp. 555 – 562

Abstract

Read online

OBJETIVO: Avaliar a ocorrência de síndrome metabólica (SM) em mulheres na pós-menopausa tratadas de câncer de mama. MÉTODOS: Estudo clínico, transversal, com 158 mulheres na pós-menopausa (amenorreia >12 meses e idade ≥45 anos) tratadas de câncer de mama e livres de doença há pelo menos cinco anos. Por meio de entrevista foram coletados dados clínicos e avaliados o índice de massa corpórea (IMC) e a circunferência da cintura (CC). Na análise bioquímica foram solicitadas dosagens de colesterol total (CT), HDL, LDL, triglicerídeos (TG), glicemia, insulina e proteína C-reativa (PCR). Foram consideradas com SM as mulheres que apresentaram três ou mais critérios diagnósticos: CC>88 cm; TG≥150 mg/dL; HDL colesterol 88 cm) afetando 54,4% (86/158) das mulheres. As pacientes sem SM tiveram maior tempo de seguimento quando comparadas àquelas com SM (pPURPOSE: To assess the occurrence of metabolic syndrome (MetS) in postmenopausal breast cancer survivors. METHODS: A total of 158 breast cancer survivors were included in this cross-sectional study. Eligibility criteria were: women with amenorrhea >12 months and age ≥45 years, treated for breast cancer and no metastasis for at least five years. Clinical history and anthropometric indicator data (body mass index (BMI), and waist circumference, (WC) were collected. Biochemical parameters, including total cholesterol, HDL, LDL, triglycerides (TG), glucose and C-reactive protein (CRP), were measured. MetS was diagnosed as the presence of at least three of the following diagnostic criteria: WC>88 cm, blood pressure≥130/85 mmHg, triglycerides≥150 mg/dl, HDL 88 cm), affecting 54.4% (86/158) of the women. The patients without MetS had a longer follow-up compared those with MetS (p0.05). CONCLUSION: Postmenopausal breast cancer survivors had a higher risk of developing metabolic syndrome and central obesity.

Keywords